<div id="readability-page-1"><div><ul> <li>Pharvaris N.V. recently reported final results from the open-label extension of its Phase 2 CHAPTER-1 trial of oral deucrictibant for hereditary angioedema, highlighting up to three years of improved quality of life, disease control, and treatment satisfaction, and reiterated plans to file an NDA for on-demand treatment in the first half of 2026.</li> <li>The data underline how an oral bradykinin B2 receptor antagonist could reshape long-term management of bradykinin-mediated angioedema, potentially offering patients a more convenient alternative to existing injectable options.</li> <li>With deucrictibant’s long-term quality-of-life benefits now in focus, we’ll examine how this clinical progress reshapes Pharvaris’ investment narrative.</li> </ul><p>Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</p><h2>What Is Pharvaris' Investment Narrative?</h2><p>To own Pharvaris, you really have to buy into one big idea: that deucrictibant can become a meaningful oral option in hereditary angioedema and possibly other bradykinin‑mediated conditions, justifying years of losses and dilution before any commercial revenue shows up. The new CHAPTER‑1 open‑label extension data strengthens that story on the prophylaxis side by adding up to three years of quality‑of‑life and disease‑control evidence, but it does not fundamentally change the near‑term catalyst stack, which still centers on the planned 2026 NDA filing for on‑demand use and upcoming Phase 3 readouts. Where it might matter is in supporting payer and clinician acceptance if regulators ultimately agree, potentially improving the commercial case, while the core risks remain unchanged: regulatory outcomes, trial replication, cash burn and future funding needs.</p><p> Despite retreating, Pharvaris' shares might still be trading above their fair value and there could be some more downside. Discover how much.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/846bc352-6836-4d16-8e44-2ad6fd4d89c5/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/846bc352-6836-4d16-8e44-2ad6fd4d89c5/chart/quote-price"/><figcaption>PHVS 1-Year Stock Price Chart</figcaption></figure> <p>The single Simply Wall St Community fair value estimate clusters around US$46.31, while recent quality‑of‑life data and the 2026 NDA timeline highlight how much depends on regulatory decisions and future financing paths; you can compare these differing views to form your own stance on Pharvaris’ potential.</p><p>Explore another fair value estimate on Pharvaris - why the stock might be worth as much as 75% more than the current price!</p><h2>Decide For Yourself</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Pharvaris research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.</li><li>Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.</li></ul><h2>Searching For A Fresh Perspective?</h2><p>These stocks are moving-our analysis flagged them today. Act fast before the price catches up:</p><ul><li>Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li><li>AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

PHVS

<p>Pharvaris N.V. has reported positive final results from its Phase 2 CHAPTER-1 trial of oral deucrictibant for hereditary angioedema, showing improved quality of life and disease control over three years. The company plans to file an NDA for on-demand treatment in 2026. While the new data strengthens the investment narrative, risks remain regarding regulatory outcomes and funding needs. Current stock prices may be above fair value, with differing opinions on the stock's potential. The analysis emphasizes the importance of regulatory decisions and future financing paths for Pharvaris' success.</p>

Simplywall

iShares Biotechnology ETF

Pharvaris BV

Invesco Biotechnology & Genome ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

VG Health

VanEck Biotech ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Can Pharvaris (PHVS) Turn Deucrictibant’s Phase 2 Extension Data Into a Durable Franchise Advantage?